Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Abbott Pays Top Dollar For Galapagos’ Autoimmune Drug

Feb 29 2012

• By Paul Bonanos

Related Content

Abbott Pays $400 Million Upfront For Reata’s Preclinical AIM Programs

Dec 12 2011

Abbott Refreshes Rheumatoid Arthritis Strategy By Licensing Biotest's Phase II Candidate

Jun 22 2011

Abbott Pays $450MM Up-Front For Rights To Reata's CKD Drug

Sep 23 2010

Abbott To Split Into Two Publicly Traded Companies Over Next 12 Months

Oct 19 2011

Tofacitinib Data Is In: As Effective As Humira, But Safety Remains A Question

Sep 12 2011

JAK Of All Trades: Janus Kinase Inhibitors Are Ready, Willing And Orally Available For Many Diseases

Feb 01 2011

Related Companies

Abbott

Galapagos NV

Pfizer Inc.

Biotest AG

Reata Pharmaceuticals, Inc.

GSK plc

Additional Topics

United States Belgium Europe Business Strategies Clinical Trials Deals BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window